A5052825850- Pancreatic and Hepatic Oncology Research
- Pancreatitis Pathology and Treatment
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Gallbladder and Bile Duct Disorders
- Gastrointestinal disorders and treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Renal cell carcinoma treatment
- Pediatric Hepatobiliary Diseases and Treatments
- Epigenetics and DNA Methylation
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Pancreatic function and diabetes
- Colorectal Cancer Treatments and Studies
- Liver Disease Diagnosis and Treatment
- Cancer Research and Treatments
- Colorectal Cancer Screening and Detection
- Biliary and Gastrointestinal Fistulas
- Protease and Inhibitor Mechanisms
- Peptidase Inhibition and Analysis
- Angiogenesis and VEGF in Cancer
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- Esophageal and GI Pathology
Heidelberg University
2016-2025
University Hospital Heidelberg
2017-2025
University of Liverpool
2013-2024
Champalimaud Foundation
2023-2024
National Institute of Diabetes and Digestive and Kidney Diseases
2024
National Institutes of Health
2015-2024
Hippocration General Hospital
2024
National and Kapodistrian University of Athens
2024
Chirurgische Universitätsklinik Heidelberg
2018-2023
National Center for Tumor Diseases
2023
The effect of adjuvant treatment on survival in pancreatic cancer is unclear. We report the final results European Study Group for Pancreatic Cancer 1 Trial and update interim results.In a multicenter trial using two-by-two factorial design, we randomly assigned 73 patients with resected ductal adenocarcinoma to chemoradiotherapy alone (20 Gy over two-week period plus fluorouracil), 75 chemotherapy (fluorouracil), 72 both chemotherapy, 69 observation.The analysis was based 237 deaths among...
BackgroundThe ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have shown better tumour response capecitabine alone advanced or metastatic We aimed determine efficacy safety compared monotherapy for cancer.MethodsWe did a phase 3, two-group, open-label, multicentre, randomised at 92 hospitals England, Scotland, Wales,...
Adjuvant fluorouracil has been shown to be of benefit for patients with resected pancreatic cancer. Gemcitabine is known the most effective agent in advanced disease as well an cancer.To determine whether or gemcitabine superior terms overall survival adjuvant treatment following resection cancer.The European Study Group Pancreatic Cancer (ESPAC)-3 trial, open-label, phase 3, randomized controlled trial conducted 159 cancer centers Europe, Australasia, Japan, and Canada. Included ESPAC-3...
Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic cancer. This open-label study was designed to compare the overall survival (OS) of patients randomly assigned GEM alone or plus capecitabine (GEM-CAP).Patients with previously untreated histologically cytologically proven locally metastatic carcinoma pancreas a performance status <or= 2 were recruited. Patients GEM-CAP. The primary outcome measure survival. Meta-analysis published studies also...
To assess the influence of resection margins on survival for patients with resected pancreatic cancer treated within context adjuvant European Study Group Pancreatic Cancer-1 (ESPAC-1) study.Pancreatic is associated a poor long-term rate only 10% to 15% after resection. Patients positive microscopic (R1) have worse survival, but it not known how they fare in studies.ESPAC-1, largest randomized study resectable ever performed, set out look at roles chemoradiation and chemotherapy....
New biomarkers of liver injury are required in the clinic and preclinical pharmaceutical evaluation. Previous studies demonstrate that two liver-enriched microRNAs (miR-122 miR-192) promising acetaminophen-induced acute (APAP-ALI) mice. We have examined these molecules, for first time, humans with APAP poisoning. Serum miR-122 miR-192 were substantially higher APAP-ALI patients, compared to healthy controls (median ΔΔCt [25th, 75th percentile]) (miR-122: 1,265 [491, 4,270] versus 12.1 [7.0,...